|
A Study of Treatment Delivery Preference In People With Kidney Cancer
RECRUITINGPhase 4Sponsored by Memorial Sloan Kettering Cancer Center
Actively Recruiting
PhasePhase 4
SponsorMemorial Sloan Kettering Cancer Center
Started2026-09-24
Est. completion2030-09-24
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07872553
Summary
The purpose of this study is to see if people prefer immunotherapy treatment for kidney cancer delivered intravenously or subcutaneously and if it is practical for participants to receive labs at home and have a video (telehealth) visit with their doctor prior to their day of treatment.
Eligibility
Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria: Patients: A patient cannot be considered eligible for this study unless ALL of the following conditions are met. * Patient is receiving standard of care treatment for renal cell carcinoma for one of the following indications: 1) NIVO monotherapy as maintenance, after ipilimumab and NIVO induction (up to 4 doses), 2) NIVO monotherapy as single-agent treatment, OR 3) adjuvant PEMBRO monotherapy or combination therapy with belzutifan. Of note, patient does not need to be newly initiating treatment to be eligible for this study. * For patients on NIVO monotherapy or PEMBRO (Groups 2 and 3 above), they must have received at least 1 dose as a standard of care to be eligible * Patient has at least 6 doses of planned treatment left as standard of care that can be given on protocol (either NIVO or PEMBRO) * For example, standard of care for adjuvant PEMBRO is 1 year of therapy which can be given at 3 (17 doses) or 6 (9 doses) week intervals. Patients can enter this trial after starting treatment but must have at least 6 doses of treatment left to be eligible. * For example, standard of care for maintenance NIVO (after ipilimumab + NIVO) is typically about 2 years of therapy. NIVO can be given at 2 (about 52 doses) or 4 week (about 26 doses) intervals. * Age ≥ 18 * Ability to speak and read English because we do not have the resources to translate all materials into other languages * Patient must be able to provide written informed consent, or a legal authorized representative (LAR)/caregiver must be identified to provide consent in cases where the patient cannot. * Patients are unable to receive investigational agents on other clinical trial protocols Providers (Medical Oncologists): * Medical oncologists in the genitourinary medical oncology department will be involved with this study if they are the treating investigator for patients who consent to this study * The medical oncologists who are involved in this will be asked to complete surveys
Conditions3
CancerKidney CancerRenal Cell Carcinoma
Interventions4
Locations7 sites
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)
Sahil Doshi, MD646-422-4341
Memorial Sloan Kettering Monmouth (All Protocol Activities)
Sahil Doshi, MD646-422-4341
Memorial Sloan Kettering Bergen (All Protocol Activities)
Sahil Doshi, MD646-422-4341
Memorial Sloan Kettering Cancer Center Suffolk - Commack (All Protocol Activities)
Sahil Doshi, MD646-422-4341
Memorial Sloan Kettering Westchester (All Protocol Activities)
Sahil Doshi, MD646-422-4341
Find trials near these locations
Related trials
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study — LaNova Medicines Zhejiang Co., Ltd.
- A Pilot Study Investigating Upfront Adaptive Immunotherapy Approach in Children, Adolescent and Young Adult (CAYA) Patients With Replication-Repair Deficient (RRD) High-Grade Gliomas (HGG) — Daniel Morgenstern
- A Study of TRK-950 in Patients With Advanced Solid Tumors — Toray Industries, Inc
- Adjuvant Immunotherapy After Salvage Surgery in Head and Neck Squamous Cell Carcinoma — Gustave Roussy, Cancer Campus, Grand Paris
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study) — Melanoma Institute Australia
- Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC Patients — Consorzio Oncotech
- Brachytherapy Followed by Nivolumab Prior to Surgery in Rectal Cancer — Dr. Te Vuong
- CARE1 Pragmatic Clinical Trial — Gustave Roussy, Cancer Campus, Grand Paris
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
Actively Recruiting
PhasePhase 4
SponsorMemorial Sloan Kettering Cancer Center
Started2026-09-24
Est. completion2030-09-24
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations7 sites
View on ClinicalTrials.gov →
NCT07872553